Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 2/20 | 0.47 |
| ▸ | F10 | P00742 | 6/20 | 0.44 |
| ▸ | XIAP | P98170 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10183595 | 1.00 | NPY1R (0.47) | NPY1RF10XIAPSMN1; SMN2MEN1 | |
| SCHEMBL5133139 | 0.89 | NPY1R (0.43) | NPY1RF10XIAPSMN1; SMN2MEN1 | |
| SCHEMBL649727 | 0.87 | ALDH1A1 (0.48) | NPY1RF10XIAPSMN1; SMN2MEN1 | |
| SCHEMBL5133148 | 0.87 | NPY1R (0.47) | NPY1RF10XIAPSMN1; SMN2MEN1 | |
| SCHEMBL5132775 | 0.87 | ALDH1A1 (0.48) | NPY1RF10XIAPSMN1; SMN2MEN1 | |
| SCHEMBL649728 | 0.87 | ALDH1A1 (0.48) | NPY1RF10XIAPSMN1; SMN2MEN1 | |
| SCHEMBL5134064 | 0.87 | NPY1R (0.54) | NPY1RXIAPSMN1; SMN2MEN1KMT2A | |
| SCHEMBL5651206 | 0.85 | FNTA (0.49) | NPY1RF10XIAPSMN1; SMN2MEN1 | |
| SCHEMBL5651200 | 0.85 | FNTA (0.49) | NPY1RF10XIAPSMN1; SMN2MEN1 | |
| SCHEMBL4870965 | 0.84 | NPY1R (0.43) | NPY1RF10XIAPSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7276608-B2 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276608-B2 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276608-B2 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-20050009870-A1 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009870-A1 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | CNR2, CNR1, OPRL1 | NPY1R 326/4885F10 3174/4885XIAP 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.